The SWIFT-1 and SWIFT-2 trials demonstrated that depemokimab, as an add-on therapy, significantly reduced exacerbation and hospitalization rates in patients with type 2 inflammation asthma.

If approved, depemokimab would be the first ultra-long-acting biologic with a six-month dosing interval for the treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal ...